400,000 Shares in SciClone Pharmaceuticals, Inc. (SCLN) Acquired by OxFORD Asset Management LLP

OxFORD Asset Management LLP purchased a new position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 400,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,460,000. OxFORD Asset Management LLP owned approximately 0.77% of SciClone Pharmaceuticals as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Louisiana State Employees Retirement System grew its stake in shares of SciClone Pharmaceuticals by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 21,100 shares of the specialty pharmaceutical company’s stock worth $232,000 after purchasing an additional 100 shares in the last quarter. Arizona State Retirement System grew its stake in shares of SciClone Pharmaceuticals by 0.7% during the second quarter. Arizona State Retirement System now owns 27,000 shares of the specialty pharmaceutical company’s stock worth $297,000 after purchasing an additional 200 shares in the last quarter. Texas Permanent School Fund grew its stake in shares of SciClone Pharmaceuticals by 1.3% during the second quarter. Texas Permanent School Fund now owns 37,770 shares of the specialty pharmaceutical company’s stock worth $415,000 after purchasing an additional 502 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of SciClone Pharmaceuticals by 0.3% during the second quarter. Principal Financial Group Inc. now owns 403,714 shares of the specialty pharmaceutical company’s stock worth $4,441,000 after purchasing an additional 1,214 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of SciClone Pharmaceuticals by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 41,284 shares of the specialty pharmaceutical company’s stock worth $454,000 after purchasing an additional 1,459 shares in the last quarter. Institutional investors and hedge funds own 72.80% of the company’s stock.

SciClone Pharmaceuticals, Inc. (SCLN) opened at $11.15 on Thursday. SciClone Pharmaceuticals, Inc. has a 12 month low of $8.55 and a 12 month high of $11.43.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/400000-shares-in-sciclone-pharmaceuticals-inc-scln-acquired-by-oxford-asset-management-llp.html.

SciClone Pharmaceuticals Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply